Effects of smoking cessation on HDL function and cardiovascular biomarkers.

Effects of smoking cessation on HDL function and cardiovascular biomarkers. - Smoking cessation and HDL function

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000032552

Enrollment

Registered

2018-05-11

Start date

2018-05-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nicotine addiction

Interventions

varenicline treatment for 4 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Outpatients with nicotine addiction 2) Subjects who gave written informed consent

Exclusion criteria

Exclusion criteria: 1) Poor-controlled hypertension (DBP>110 mmHg) 2) Poor-controlled diabetes (HbA1c>8.0 %) 3) History of stroke, acute coronary syndrome or any cardiovascular diseases needed for inpatient-treatments within 6 months 4) Either level of aspartate aminotransaminase or alanine aminotransferase exceeds three-fold of the normal limits. 5) End stage renal disease 6) Symptomatic (NYHA III or IV) congestive heart failure 7) Malignancies or other diseases with poor prognosis 8) Subjects with poor-controlled psychiatric diseases 9) Subjects who are prohibited varenicline treatment 10) Subjects whose doctor in charge do not agree to join the trial

Design outcomes

Primary

Measure	Time frame
HDL cholesterol levels, cholesterol efflux capacity/antioxidant activity of HDL	—

Countries

Japan

Contacts

Public ContactMakoto Ayaori

Tokorozawa Heart Center Shintikoekimae Clinic

ayaori@ba2.so-net.ne.jp0429291801

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026